Drug Trial Radar · NCT06772597
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Actual
Start
Mar 4, 2025
Primary completion
Nov 3, 2026
Study completion Oct 30, 2030
Sponsor
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label study designed to assess the safety and efficacy of setmelanotide in patients with obesity due to Prader-Willi Syndrome (PWS) who are 6 to 65 years of age. Up to 20 patients are planned to be enrolled. Patients will take a daily subcutaneous dose of open-label setmelanotide for up to 52 weeks.
Conditions
- Prader-Willi Syndrome
- Obesity
- Hyperphagia
Interventions
SetmelanotideDrug
Setmelanotide (daily subcutaneous injection)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of adverse events (AEs)Time frame: Baseline to Week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Florida
Gainesville, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.